Cambridge, UK, 12 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech Republic for the development of novel cancer treatments targeting DNA nucleases involved in the DDR.
Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr […]
Artios Pharma Ltd (“Artios” or “the Company”) Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy Cambridge, UK, 2 November 2016. Artios Pharma Ltd., a newly launched private company focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), today announces it has strengthened its management team […]
Niall Martin, CEO and Nick Staples, CBO from Artios will be attending the AACR conference “DNA Repair: Tumor Development and Therapeutic Response” in Montreal, Canada on Nov 2-5, 2016. Artios is actively looking to expand its development pipeline with novel DDR programmes and collaborations. Please contact us at email@example.com or call on +44 (0)1223 804180 if you would like to meet […]
Artios Pharma Ltd (“Artios” or “the Company”) $33.2 Million Series A Financing from SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures to fund development of a DDR focussed pipeline Cambridge, UK, 21 September 2016. Artios Pharma Ltd., a new private company focussed […]